

Expressions and clinical significance of serum bone Gla-protein, bone alkaline phosphatase and C-terminal telopeptide of type I collagen in bone metabolism of patients with osteoporosis

Dongfeng Zhao¹, Junsheng Wang², Yining Liu³, Xinwei Liu⁴

ABSTRACT

Objective: This study aimed to evaluate the expressions and clinical significance of bone Gla-protein (BGP), bone alkaline phosphatase (B-ALP) and C-terminal telopeptide of type I collagen (CTX) in patients with osteoporosis (OP), and to provide evidence for developing individualized treatment plans.

Methods: Seventy-two OP patients in our hospital were selected as an OP group, and another 72 healthy subjects were used as a control group. Their BGP, B-ALP and CTX levels as well as bone mineral density (BMD) values were measured. The correlations between BGP, B-ALP and CTX levels and BMD values were determined.

Results: The BGP level of the OP group [(5.61±5.52) ng/ml] was significantly higher than that of the control group (P<0.05), but the levels of B-ALP and CTX did not differ significantly (P>0.05). The BMD values of femoral neck and Ward's triangle in the OP group were negatively correlated with the B-ALP levels (P<0.05). For women OP patients, the BMD values of femoral neck and Ward's triangle were also negatively correlated with the B-ALP levels (P<0.05). The BMD of femoral neck in the control group was negatively correlated with the CTX level (P<0.05).

Conclusion: Determining BGP, B-ALP and CTX levels can evaluate the bone metabolism degree, which provides evidence for clinical typing of OP and developing treatment strategies.

KEY WORDS: Osteoporosis; Bone Gla-protein; Bone alkaline phosphatase; C-terminal telopeptide of type I collagen.

doi: <http://dx.doi.org/10.12669/pjms.311.6143>

How to cite this:

Zhao D, Wang J, Liu Y, Liu X. Expressions and clinical significance of serum bone Gla-protein, bone alkaline phosphatase and C-terminal telopeptide of type I collagen in bone metabolism of patients with osteoporosis. *Pak J Med Sci* 2015;31(1):91-94.

doi: <http://dx.doi.org/10.12669/pjms.311.6143>

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Osteoporosis (OP), a systemic skeletal disease characterized by low bone mineral density (BMD) and microarchitectural deterioration of

bone tissue, induces bone fragility and increases fracture risk.¹ Especially, it is prevalent in elderly postmenopausal women.² Osteoporotic fracture is prone to development partly because prior fracture is an important independent risk factor.³ Moreover, women with extremely low BMD have much higher risks than the average. As the most serious consequence of osteoporosis, hip fracture elevates the odds of women deaths by 2-4 times in the general population, but there remains controversy over the relationship between deaths and comorbid conditions or hip fracture *per se*. Even after surviving 12 months posterior to a hip fracture, patients are subject to severe functional declines. It has previously been reported that 50%, 70%, and 87% of the women with hip fractures

1. Dongfeng Zhao,
 2. Junsheng Wang,
 3. Yining Liu,
 4. Xinwei Liu,
- 1-4: Department of Orthopedics,
The 210th Hospital of People's Liberation Army,
Dalian 116021, PR China.

Correspondence:

Xinwei Liu,
E-mail: liuxinweido@yeah.net

- * Received for Publication: July 30, 2014
- * Accepted for Publication: * September 30, 2014

failed to independently walk, transfer from one place to another, and climb stairs respectively.⁴

With unraveled pathogenic mechanism, OP has been associated with the level of calcium intake, genetic factors, bad habits and hormone secretion, etc.⁵ Particularly, the patients in critical conditions may suffer from intense pain and frequent spontaneous fractures, with significantly affected health and quality of life.⁶ Generally, OP should be treated according to the status of individuals.⁷

The levels of bone Gla-protein (BGP or osteocalcin) and bone alkaline phosphatase (B-ALP) reflect the changes of bone formation most sensitively and specifically, while that of C-terminal telopeptide of type I collagen (CTX) indicates the changes of bone resorption most satisfactorily.⁸ Earlier studies regarding bone metabolism, which relied primarily on urinary markers such as deoxypyridinoline and pyridinoline, were time-consuming and cumbersome, thus rendering the measurement imprecise. However, CTX, as a serum marker, is preferred for measuring bone resorption⁹ because it is highly correlated to bone turnover rate and available for detection in laboratory.¹⁰

Although the three biomarkers have been used to detect bone metabolism, they have seldom been utilized in clinical practice simultaneously. Thereby motivated, the expressions and clinical significance of BGP, B-ALP and CTX for OP patients were investigated in this study, aiming to provide evidence for developing individualized treatment plans.

METHODS

General information: This study has been approved by the ethics committee of the 210th Hospital of People's Liberation Army. Written informed consent was obtained from all participants and all clinical investigations have been conducted according to the principles expressed in the Declaration of Helsinki. Seventy-two patients diagnosed as OP in our hospital from March 2011 to March 2013 were selected as the OP group, including 29 males and 43 females, aged 52-71 years old (average: 60.72 ± 9.58). Another 72 healthy volunteers were randomly selected as the control group, including 32 males and 40 females, aged 49-66 years old (average: 59.18




Fig.1: General information of OP patients and controls.

± 9.31). The gender and age of the two groups did not differ significantly ($P > 0.05$) (Fig.1).

Evaluation criteria: Patients were diagnosed according to the criteria in "Chinese guideline on prevention and treatment of primary osteoporosis"¹¹ issued by Chinese Medical Association of Osteoporosis and Mineral Disease. Meanwhile, the patients with secondary hyperparathyroidism and secondary OP induced by adrenocorticotrophic hormone and diabetes, as well as those who took anti-OP agents recently were excluded.

Methods: The BGP, B-ALP and CTX levels of the two groups were measured by collecting fasting venous bloods. BGP level was detected by radioimmunoassay (Shanghai Ricky Biotechnology Co., Ltd.), and B-ALP (Shanghai Jining Industry Co., Ltd.) and CTX levels (Sirocco Biotechnology (Shanghai) Co., Ltd.) were determined by enzyme-linked immunosorbent assay. BMD values were measured by XR-600 quick scanning machine (NORLAND, USA). All the measurements were performed strictly according to "National Guide to Clinical Laboratory Procedures"¹² and instructions of apparatus and reagents.

Observation indices: The correlations between BGP, B-ALP and CTX levels and BMD values were investigated and compared.

Statistical analysis: All data were analyzed by SPSS 17.0. The measurement data were expressed as mean ± standard deviation ($\bar{x} \pm S$) and compared by t test. The correlations between BMD values and bone metabolism indices were subjected to linear correlation analysis. $P < 0.05$ was considered statistically significant.

Table-I: Comparison between bone metabolism indices.

Group	Case No. (n)	BGP (ng/ml)	B-ALP (ng/ml)	CTX (U/L)
OP group	72	5.61±5.52 ^a	0.43±0.37	31.98±12.64
Control group	72	3.24±1.28	0.37±0.42	30.71±7.53

Compared with the control group, ^a $P < 0.05$.

Table-II: Correlations between BMD values and bone metabolism indices of the OP group (r values).

Position	OP group (n=72)			Male (n=29)			Female (n=43)		
	BGP	B-ALP	CTX	BGP	B-ALP	CTX	BGP	B-ALP	CTX
Femoral neck	-0.047	-0.220 ^a	0.089	0.162	0.318	0.031	-0.186	-0.316 ^a	-0.091
Greater trochanter	0.033	-0.171	0.171	0.193	-0.158	0.018	-0.086	-0.056	-0.022
Ward's triangle	-0.094	-0.287 ^a	-0.016	0.057	0.014	-0.194	-0.206	-0.366 ^a	0.007

^aP<0.05.

Table-III: Correlations between BMD values and bone metabolism indices of the control group (r values).

Position	Control group (n=72)		
	BGP	B-ALP	CTX
Femoral neck	0.005	-0.032	-0.436 ^a
Greater trochanter	0.047	-0.195	0.208
Ward's triangle	-0.149	-0.055	-0.198

^aP<0.05.

RESULTS

Comparison between bone metabolism indices: The BGP levels of the OP group [(5.61±5.52) ng/ml] was significantly higher than that of the control group [(3.24±1.28) ng/ml] (P<0.05), but the B-ALP and CTX levels of the two groups had no significant differences (P>0.05) (Table-I).

Correlations between BMD values and bone metabolism indices of the OP group: The BMD values of femoral neck and Ward's triangle in the OP group were negatively correlated with the B-ALP levels (P<0.05). For women OP patients, the BMD values of femoral neck and Ward's triangle were also negatively correlated with the B-ALP levels (P<0.05). However, the BGP and CTX levels of OP patients were not significantly correlated with the BMD values. In the meantime, the B-ALP levels of male patients were also not significantly correlated with BMD (Table-II).

Correlations between BMD values and bone metabolism indices of the control group: The BMD values of femoral neck were significantly negatively correlated with the CTX level (P<0.05), whereas it were not significantly correlated with the BGP and B-ALP levels. In contrast, the BMD values of greater trochanter and Ward's triangle were not significantly correlated with the BGP and B-ALP levels (Table-III).

DISCUSSION

There is a dynamic equilibrium between human bone formation and resorption, which maintains stable bone mass and BMD. In case of hormone level changes and calcium deficiency, the equilibrium is destroyed, thus inducing OP by decreasing bone

mass and BMD. OP, which is prevalent among the elderly and menopause women, is associated with enhanced bone resorption with/without deficient bone formation.^{13,14} With disease progression, OP patients are prone to bone fracture owing to remarkably reduced bone mineral content and intensity, the health and quality of life of whom are thus evidently affected.^{15,16} Hence, OP patients should be treated based on the pathogenesis of individuals.

OP occurs when bone resorption exceeds formation. BGP and B-ALP levels are related with bone formation, and CTX level is related with bone resorption.¹⁷ Clinically, the disease can be classified as primary type 1 OP (postmenopausal OP) and primary type 2 OP (senile osteoporosis). Type 1 OP is associated with postmenopausal endocrine changes, accompanied by raised levels of bone metabolism indices. Contrarily, type 2 OP, which results from ageing, is concomitant with normal or reduced levels of bone metabolism indices.¹⁸ Clarifying bone metabolism changes can guide clinical administration. Despite the ability to detect bone metabolism, biopsy, which is traumatic, cannot be widely applied in clinical practice.¹⁹ Therefore, we herein detected the variations of bone metabolism indices.

Although bone metabolism indices cannot diagnose OP, they are capable of evaluating bone turnover rate.²⁰ In this study, only the BGP level of the OP group was significantly higher than that of the control group, indicating most enrolled patients were type 1 OP. In the OP group, the B-ALP levels were negatively correlated with the BMD values of femoral neck and Ward's triangle. Although OP women had identical outcomes, OP men did not have such correlations. The findings reveal that OP patients should be treated according to their own pathophysiological conditions, being consistent with a previous study.²¹ Furthermore, we herein combined three eligible biomarkers for detecting bone metabolism, thus allowing this study valuable.^{22,23}

In summary, bone metabolism can be evaluated by detecting BGP, B-ALP and CTX levels, which

inspires more thorough clinical typing and development of treatment protocols. Further studies on combining the three indices in OP detection are still ongoing.

Conflicts of interest: The authors declare no conflicts of interest.

REFERENCES

1. National osteoporosis society. <http://www.nos.org.uk/page.aspx?pid=328>.
2. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med*. 2009;361(8):756-765. doi: 10.1056/NEJMoa0809493.
3. Tuck SP, Francis RM. Osteoporosis. *Postgrad Med J*. 2002;78(923):526-532. doi:10.1136/pmj.78.923.526.
4. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. *Arch Intern Med*. 2010;170(9):765-771. doi: 10.1001/archinternmed.2010.94.
5. Rizzoli R, Bianchi ML, Garabédian M, McKay HA, Moreno LA. Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. *Bone*. 2010;46(2):294-305. doi: 10.1016/j.bone.2009.10.005.
6. Papaioannou A, Kennedy CC, Ioannidis G, Sawka A, Hopman WM, Pickard L, et al. The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. *Osteoporos Int*. 2009;20(5):703-714. doi: 10.1007/s00198-008-0743-7.
7. Baron R, Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. *J Clin Endocrinol Metab*. 2012;97(2):311-325. doi: 10.1210/jc.2011-2332.
8. Wheeler G, Elshahaly M, Tuck SP, Datta HK, van Laar JM. The clinical utility of bone marker measurements in osteoporosis. *J Transl Med*. 2013;11:201. doi: 10.1186/1479-5876-11-201.
9. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garner P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. *Osteoporos Int*. 2011;22(2):391-420. doi: 10.1007/s00198-010-1501-1.
10. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. *J Oral Maxillofac Surg*. 2007;65(12):2397-2410. doi:10.1016/j.joms.2008.01.054.
11. Chinese Medical Association of Osteoporosis and Mineral Disease. Chinese guideline on prevention and treatment of primary osteoporosis. 2006;1-5.
12. Ministry of Health of the People's Republic of China. National Guide to Clinical Laboratory Procedures (3rd edition), 2006.
13. King GA, Deemer SE, Thompson DL. Relationship between leptin, adiponectin, bone mineral density, and measures of adiposity among pre-menopausal Hispanic and Caucasian women. *Endocr Res*. 2010;35(3):106-117. doi: 10.3109/07435800.2010.496090.
14. Feng X, McDonald JM. Disorders of bone remodeling. *Annu Rev Pathol*. 2011;6:121-145. doi: 10.1146/annurev-pathol-011110-130203.
15. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *CMAJ*. 2010;182(17):1864-1873. doi: 10.1503/cmaj.100771.
16. Bolton KL, Egerton T, Wark J, Wee E, Matthews B, Kelly A, et al. Effects of exercise on bone density and falls risk factors in post-menopausal women with osteopenia: a randomised controlled trial. *J Sci Med Sport*. 2012;15(2):102-109. doi: 10.1016/j.jsams.2011.08.007.
17. Eastell R, Hannon RA. Biomarkers of bone health and osteoporosis risk. *Proc Nutr Soc*. 2008;67(2):157-162. doi: 10.1017/S002966510800699X.
18. Sarzi-Puttini P, Cimmino MA, Scarpa R, Caporali R, Parazzini F, Zaninelli A, et al. Osteoarthritis: an overview of the disease and its treatment strategies. *Semin Arthritis Rheum*. 2005;35(1 Suppl 1):1-10. doi: 10.1016/j.semarthrit.2005.01.013.
19. Recker RR, Marin F, Ish-Shalom S, Möricke R, Hawkins F, Kapetanos G, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. *J Bone Miner Res*. 2009;24(8):1358-1368. doi: 10.1359/jbmr.090315.
20. Bieglmayer C, Dimai HP, Gasser RW, Kudlacek S, Obermayer-Pietsch B, Woloszczuk W, et al. Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group. *Wien Med Wochenschr*. 2012;162(21-22):464-477. doi: 10.1007/s10354-012-0133-9.
21. Yang F, Shan YM, Shen Y, Wan HY. Clinical significance on the combined determination of bone biochemical markers in osteoporosis. *Lab Med*. 2010;25:768-770.
22. Lateef M, Baig M, Azhar A. Estimation of serum osteocalcin and telopeptide-C in postmenopausal osteoporotic females. *Osteoporos Int*. 2010;21(5):751-755. doi: 10.1007/s00198-009-1001-3.
23. Lumachi F, Orlando R, Fallo F, Basso SM. Relationship between bone formation markers bone alkaline phosphatase, osteocalcin and amino-terminal propeptide of type I collagen and bone mineral density in elderly men. Preliminary results. *In Vivo*. 2012;26(6):1041-1044.

Authors contribution:

XL: Conceived, designed the experiments and prepared the manuscript.

DZ, JW, YL: Performed the experiments and analyzed the data.